MA38482B1 - Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine - Google Patents
Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraineInfo
- Publication number
- MA38482B1 MA38482B1 MA38482A MA38482A MA38482B1 MA 38482 B1 MA38482 B1 MA 38482B1 MA 38482 A MA38482 A MA 38482A MA 38482 A MA38482 A MA 38482A MA 38482 B1 MA38482 B1 MA 38482B1
- Authority
- MA
- Morocco
- Prior art keywords
- sphingosine
- migraine
- pyridin
- psoriasis
- agonists
- Prior art date
Links
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 title 1
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 208000019695 Migraine disease Diseases 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13159482 | 2013-03-15 | ||
| PCT/IB2014/059794 WO2014141171A1 (en) | 2013-03-15 | 2014-03-14 | Pyridin-4-yl derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38482A1 MA38482A1 (fr) | 2017-12-29 |
| MA38482B1 true MA38482B1 (fr) | 2018-11-30 |
Family
ID=47877933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38482A MA38482B1 (fr) | 2013-03-15 | 2014-03-14 | Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine |
Country Status (33)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| TWI662030B (zh) | 2013-01-15 | 2019-06-11 | 英塞特控股公司 | 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| ES2770348T3 (es) | 2015-05-20 | 2020-07-01 | Idorsia Pharmaceuticals Ltd | Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| WO2017004610A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| JP5253401B2 (ja) * | 2006-09-07 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節薬としてのピリジン−４−イル誘導体 |
| CL2007002594A1 (es) | 2006-09-08 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . |
| CA2662673A1 (en) | 2006-09-21 | 2008-03-27 | Martin Bolli | Phenyl derivatives and their use as immunomodulators |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| EP2195311B1 (en) | 2007-08-17 | 2011-03-23 | Actelion Pharmaceuticals Ltd. | Pyridine derivatives as s1p1/edg1 receptor modulators |
| CN101970420B (zh) | 2007-10-04 | 2014-09-24 | 默克雪兰诺有限公司 | 噁二唑衍生物 |
| BRPI0818804A2 (pt) | 2007-11-01 | 2015-04-22 | Actelion Pharmaceuticals Ltd | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. |
| CN101965345B (zh) | 2008-03-06 | 2014-05-28 | 埃科特莱茵药品有限公司 | 吡啶化合物 |
| EP2262800A1 (en) | 2008-03-06 | 2010-12-22 | Actelion Pharmaceuticals Ltd. | Novel pyrimidine-pyridine derivatives |
| JP5435745B2 (ja) | 2008-03-07 | 2014-03-05 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節剤としてのピリジン−２−イル誘導体 |
| MX2010009645A (es) | 2008-03-07 | 2010-09-28 | Actelion Pharmaceuticals Ltd | Derivados novedosos de aminometil benceno. |
| PT2291080E (pt) * | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| EP2403849B1 (en) | 2009-03-03 | 2014-07-16 | Merck Serono S.A. | Oxazole pyridine derivatives useful as S1P1 receptor agonists |
| TWI410421B (zh) | 2009-07-16 | 2013-10-01 | Actelion Pharmaceuticals Ltd | 吡啶－４－基衍生物 |
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| CA2818470C (en) | 2011-01-19 | 2019-03-05 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
-
2014
- 2014-03-14 HR HRP20171763TT patent/HRP20171763T1/hr unknown
- 2014-03-14 EA EA201500931A patent/EA029309B1/ru not_active IP Right Cessation
- 2014-03-14 UA UAA201510003A patent/UA115357C2/uk unknown
- 2014-03-14 CA CA2900910A patent/CA2900910C/en active Active
- 2014-03-14 JP JP2015562523A patent/JP6387361B2/ja not_active Expired - Fee Related
- 2014-03-14 NZ NZ713080A patent/NZ713080A/en not_active IP Right Cessation
- 2014-03-14 MA MA38482A patent/MA38482B1/fr unknown
- 2014-03-14 KR KR1020157028486A patent/KR102212975B1/ko not_active Expired - Fee Related
- 2014-03-14 AU AU2014229217A patent/AU2014229217B2/en not_active Ceased
- 2014-03-14 WO PCT/IB2014/059794 patent/WO2014141171A1/en not_active Ceased
- 2014-03-14 LT LTEP14715427.2T patent/LT2970236T/lt unknown
- 2014-03-14 NO NO14715427A patent/NO2970236T3/no unknown
- 2014-03-14 SG SG11201507227UA patent/SG11201507227UA/en unknown
- 2014-03-14 BR BR112015023161-6A patent/BR112015023161B1/pt not_active IP Right Cessation
- 2014-03-14 SI SI201430428T patent/SI2970236T1/sl unknown
- 2014-03-14 MX MX2015012293A patent/MX363545B/es unknown
- 2014-03-14 AR ARP140101131A patent/AR095523A1/es active IP Right Grant
- 2014-03-14 TW TW103109288A patent/TWI623534B/zh not_active IP Right Cessation
- 2014-03-14 EP EP14715427.2A patent/EP2970236B1/en active Active
- 2014-03-14 MY MYPI2015703154A patent/MY173573A/en unknown
- 2014-03-14 DK DK14715427.2T patent/DK2970236T3/en active
- 2014-03-14 US US14/777,444 patent/US9617250B2/en active Active
- 2014-03-14 PL PL14715427T patent/PL2970236T3/pl unknown
- 2014-03-14 HU HUE14715427A patent/HUE035154T2/en unknown
- 2014-03-14 PT PT147154272T patent/PT2970236T/pt unknown
- 2014-03-14 ES ES14715427.2T patent/ES2649475T3/es active Active
- 2014-03-14 CN CN201480016238.1A patent/CN105189487B/zh not_active Expired - Fee Related
-
2015
- 2015-09-09 IL IL241363A patent/IL241363B/en active IP Right Grant
- 2015-09-11 CL CL2015002620A patent/CL2015002620A1/es unknown
- 2015-09-14 SA SA515361104A patent/SA515361104B1/ar unknown
- 2015-09-14 PH PH12015502118A patent/PH12015502118A1/en unknown
- 2015-10-14 ZA ZA2015/07657A patent/ZA201507657B/en unknown
-
2017
- 2017-11-24 CY CY20171101239T patent/CY1119619T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38482A1 (fr) | Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine | |
| MA37959A2 (fr) | Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih | |
| EA201990240A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
| MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
| MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| EP2875024A4 (en) | HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES | |
| MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MX369694B (es) | Derivados de bencimidazol sulfonamidas como agonistas inversos del receptor gamma huerfano relacionado con el retinoide por gamma (t). | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MX374758B (es) | Inhibidores de tirosina cinasa de bruton. | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA38857B1 (fr) | Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone | |
| MX374759B (es) | Inhibidores de tirosina cinasa de bruton. |